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Increased matrix metalloproteinase activity after canine
cardiopulmonary bypass is suppressed by a nitric oxide
scavenger
Irvin Mayers, MD,a Thomas Hurst, MVS,b Anna Radomski, MD,c David Johnson, MD, MPH,d Simon Fricker, PhD,e
Gary Bridger, PhD,e Beth Cameron, PhD,e Marilyn Darkes, BSc,e and Marek W. Radomski, MD, PhDc
Objectives: We tested whether nitric oxide scavenging with a ruthenium-based
compound (AMD6221) would improve hemodynamics and alter nitric oxide syn-
thase and matrix metalloproteinase activities in a canine model of cardiopulmonary
bypass.
Methods: Dogs were randomized to either cardiopulmonary bypass (n  12) or
control (n  12) groups. They were further randomized to receive a continuous
infusion of AMD6221 or placebo. Cardiopulmonary bypass was maintained for 90
minutes, and then, 4 hours later, dogs were killed. Cardiac, lung, and brain sections
were snap frozen in liquid nitrogen for determination of nitric oxide synthase, matrix
metalloproteinase 2, and matrix metalloproteinase 9 activities.
Results: After cardiopulmonary bypass, 3 of 6 placebo-treated (cardiopulmonary
bypass–placebo) and 0 of 6 AMD6221-treated (cardiopulmonary bypass–6221)
animals required phenylephrine infusion to maintain a predetermined blood pressure
(P  .05). Total fluid administration was lower in the cardiopulmonary bypass–
6221 group compared with that in the cardiopulmonary bypass–placebo group
(983  134 vs 1617  254 mL, respectively; P  .005). After cardiopulmonary
bypass, matrix metalloproteinase 2 and matrix metalloproteinase 9 activities in the
lung, left ventricle, and left atrium were decreased in the cardiopulmonary bypass–
6221 group compared with that in the cardiopulmonary bypass–placebo group (P 
.05). Ca2-independent nitric oxide synthase activity and matrix metalloproteinase
2 activity in the brain were also lower (P  .05) in the cardiopulmonary bypass–
SCV group. Finally, neutrophil expression of CD18, an adhesion complex, was
lower at 4 hours after cardiopulmonary bypass in the cardiopulmonary bypass–6221
group compared with that in the cardiopulmonary bypass–placebo group (38  27
vs 81  11; P  .05).
Conclusions: We found that (1) infusion of an nitric oxide scavenger, AMD6221,
was associated with improved predefined hemodynamics; (2) cardiopulmonary
bypass increased activities of Ca2-independent nitric oxide synthase and matrix
metalloproteinases in multiple organs; and (3) AMD6221 could ameliorate the
increased generation of nitric oxide and increased matrix metalloproteinase activi-
ties.
Cardiopulmonary bypass (CPB) initiates an inflammatory injury1associated with increased proinflammatory cytokines.2 Proinflam-matory cytokines can activate downstream signaling, leading togeneration and release of other inflammatory mediators. Weshowed that activities of 2 enzyme families, nitric oxide synthase(NOS) and gelatinases (matrix metalloproteinase [MMP] 2 and
MMP-9) are increased in human myocardial tissue after CPB.3 Increased MMP
activities and increased NOS products are independently associated with cardiac
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dysfunction.4,5 A new class of drugs that binds plasma nitric
oxide (NO) to the metal ruthenium have been recently
developed.6 In the current study we showed that treatment
with AMD6221, an NO scavenger, can ameliorate some of
the CPB-induced increases in MMPs and improve postop-
erative hemodynamics.
Materials and Methods
Animal Preparation
These studies were approved by the University of Saskatchewan
Animal Care Committee and complied with published National
Institutes of Health guidelines. Mongrel dogs (weight 20-25 kg)
were anesthetized with pentobarbital (15 mg/kg), intubated, and
mechanically ventilated (Harvard Model 607). Anesthesia was
maintained by means of continuous infusion of pentobarbital (1.0
mg  kg1  h1), morphine (0.1 mg  kg1  h1), and
vecuronium bromide (0.1 mg kg1 h1). A pulmonary artery
catheter was used to measure mean pulmonary artery pressure,
pulmonary capillary wedge pressure, mean right atrial pressure
(PRA), and cardiac output (CO). Mean systemic artery pressure
(PSA) and arterial blood gas sampling were obtained through a
femoral artery catheter.
We have previously described our CPB model.7 Briefly, the
heart was exposed through a midline sternotomy. After hepariniza-
tion (5000 U administered intravenously followed by 1000 U/h
administered intravenously), catheters were placed in the left and
right atria to complete the bypass circuit. A balloon angioplasty
catheter (6F) positioned proximal to the aortic valve through the
right internal carotid artery acted to internally crossclamp the aorta
when inflated. CPB was initiated by using a membrane oxygenator
(Capiox Hollow Fiber Oxygenator) and a blood pump (Sarns
Model 5000 Console) at 100 mL/kg flow. Cold (7°C-8°C) ante-
grade cardioplegia solution was delivered, and then the aorta was
occluded by means of inflation of the angioplasty balloon. Blood
cardioplegia (BCD4 Sharely), initially with 30 mEq of KCl and
subsequently decreasing the concentration to 10 mEq of KCl, was
continuously administered to eliminate electrical activity. The
animals were cooled (24°C), and the aortic occlusion was main-
tained for a further 50 minutes. Before deflating the aortic balloon,
150 mL of warm cardioplegic solution without KCl supplementa-
tion was administered. Then the angioplasty balloon was deflated,
mechanical ventilation was resumed, and the animals were
warmed over 30 minutes. Therefore CPB lasted a total of 90
minutes. We prospectively chose to maintain PSA at greater than
60 mm Hg by first increasing PRA to 15 mm Hg by means of fluid
administration and then infusing phenylephrine. The animals were
maintained for 4 hours after CPB.
Experimental Groups
Dogs were randomized to CPB (n  12) or control (n  12)
groups. Dogs receiving CPB were further randomized to receive a
continuous infusion of AMD6221, an NO scavenger (CPB-6221
group, n 6), or to receive a placebo (CPB-placebo group, n 6).
AMD6221 was continuously infused (128 mg  kg1  h1),
starting before the sternotomy and ending 30 minutes after termi-
nation of CPB (Figure 1). We selected this dose on the basis of
pilot data that examined the efficacy of AMD6221 as an NO
scavenger (data not shown).
The biochemical and physiologic effects of AMD6221 in nor-
mal dogs have previously not been characterized. Therefore we
treated the control dogs to a similar protocol but did not perform
a sternotomy or placement of CPB-related catheters. The drug
infusions (AMD6221 or placebo) were administered over times
similar to those of the CPB-treated animals. At the conclusion of
the studies, all animals were killed by means of barbiturate over-
dose. Biopsy specimens (0.5 cm2) from the left ventricle, left
atrium, lung (right lower lobe), and brain (cerebral cortex) were
obtained, frozen in liquid nitrogen, and stored at 70°C until
assayed (see below).
Measurements and Calculations
After catheter insertions, baseline blood samples were obtained for
routine hematology, biochemistry, and blood gas measurement
(Table 1). Hemodynamic measurements, including CO, PSA, pul-
monary artery pressure, pulmonary capillary wedge pressure,
mean left atrial pressure, and PRA, were repeated at 1 and 4 hours
after bypass and as needed to maintain our predetermined hemo-
dynamic goals. Neutrophil expression of CD18 was measured with
flow cytometry (FACScan), as previously described.8 Briefly, after
cells were prepared, they were incubated with an irrelevant, iso-
type-matched, FITC-conjugated rat monoclonal antibody
(MCA1125F, Serotech Ltd) or FITC-conjugated rat anti-human
CD18 antibody (MCA503F, Serotech) that cross-reacted with ca-
nine. Flow cytometric analysis was restricted to neutrophils on the
basis of forward-angle and right-angle light scatter. Neutrophil
CD18 expression was determined as the percentage of cells with a
fluorescence exceeding that of cells reacted with the irrelevant
isotype-matched control.
NOS activity was measured in homogenized tissue samples, as
previously described.9 Briefly, tissue aliquots were incubated with
L[U-14C]-arginine (Amersham) for 20 minutes in the appropriate
buffer. NOS-dependent L-citrulline formation expressed as pico-
moles per minute per milligram of protein was used as an index of
enzyme activity. A Ca2-chelating agent (ethyleneglycol-bis-[-
aminoethylether]-N,N,N,N-tetraacetic acid, 1 mmol/L) was used
to differentiate between Ca2-dependent and Ca2-independent
NOS activities of enzymes. Tissue MMP activity was measured by
means of zymography, as previously described,10 by using 7%
SDS-PAGE with copolymerized gelatin as a substrate. Enzyme
activity was expressed as arbitrary units per milligram of protein.
Tissue NOS and MMP activities were obtained at only one time
point, and that was after the animals were killed.
Statistics
Data (means  SD) were compared between periods and groups
with a 1-way or 2-way analysis of variance, as appropriate, and
when the F statistic showed a significant difference, a Student-
Newman-Keuls multiple comparison test was used to determine
specific group and period differences. We prospectively limited the
possible number of comparisons to limit required correction factor.
Spearman correlation was used to assess the interaction between
CD18 expression and NOS or MMP activity.
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Results
Hemodynamics and Gas Exchange
PSA and CO decreased, whereas systemic vascular resis-
tance increased over time in the CPB groups (Table 1). To
achieve our predefined hemodynamic end points (PSA 60
mm Hg and PRA 15 mm Hg), 3 of 6 CPB-placebo animals
required a phenylephrine infusion compared with 0 of 6 the
CPB-6221 animals (P .05). Total fluid administration was
reduced in the NO scavenger groups compared with that in
the placebo groups.
Comparing baseline values to 4 hours after CPB (Table
2), PO2 decreased in the CPB-6221 group and the CPB-
placebo group (P  .05), and intrapulmonary shunting in-
creased (19%  10% vs 18%  14%, respectively; P  .05).
Neutrophils, as a percentage of white blood cell counts, in-
creased from baseline to 4 hours after CPB in the CPB-placebo
group (66% 7% to 83% 5%, P .03). CD18 expression
at 4 hours after CPB was lower in the CPB-6221 group
compared with that in the CPB-placebo group (P  .05).
NOS and MMP Activities
CPB did not significantly influence Ca2-dependent NOS
activities in heart, brain, and lung tissues (Figures 1 and 2).
However, CPB significantly increased Ca2-independent
NOS activities (P  .05) compared with control groups in
the heart, brain, and lung. Administration of AMD6221 did
not significantly influence NOS activities in the lung, ven-
tricular, or atrial samples (Figure 2), but brain Ca2-inde-
pendent NOS activity was significantly reduced (P .05) in
the CBP-6221 group compared with in the CPB-placebo
group. MMP-2 and MMP-9 activities were significantly
(P  .05) increased in the CPB-placebo group compared
with in the control-placebo group in the heart and lung
(Figure 3). Only MMP-2 was significantly (P  .05) in-
creased in the brain in the CPB-placebo group compared
with in the control-placebo group (Figure 4). MMP activity
was significantly reduced in the CPB-6221 group compared
with that in the CPB-placebo group (P  .05). MMP activ-
ity, except brain MMP-9, was positively correlated to CD18
peak expression (  0.46-0.73, P  .005). NOS activity
was not correlated to CD18 peak expression (P  .05).
Discussion
Experimental Model
Our model of CPB differs in some aspects from the human
setting. The dogs, unlike human subjects, did not have
Figure 1. Mean  SD values of Ca2-dependent and Ca2-independent NOS activity. Values are shown for the left
atrium and left ventricle. *Significant difference (P < .05) between CPB (filled bars) and control (open bars) groups.
#Significant difference between control and AMD6221-treated groups (P < .05).
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known preexisting heart disease. Intraoperative bypass
grafting was not performed, and aortic flow was occluded
with an internal rather than external crossclamp. We previ-
ously showed that sham bypass can independently activate
inflammatory pathways,8 and therefore our control animals
were not subjected to sham CPB. Within these limitations,
our findings are representative of the human CPB proce-
dure. Of note, the myocardial changes of NOS and MMP
activities in these canine studies mimic those found after
human CPB.3 This allows the extrapolation of these broader
animal findings to the human setting.
AMD6221 represents a new class of drugs on the basis of
the ability of a ruthenium(III) polyaminocarboxylate com-
plex to react rapidly with NO to form a stable and inert
ruthenium(II) nitrosyl complex. The effects of AMD6221
on NO have been studied by using a murine macrophage
cell line.11 AMD6221 was shown to rapidly and irreversibly
bind NO without influencing inducible NOS (iNOS) activity
or iNOS expression. These compounds might have other
unforeseen actions, but it is clear that they can selectively
bind NO and thereby reduce plasma NO concentrations.
NOS and CPB
The NOS family of enzymes includes calcium-dependent
(neuronal-type NOS and endothelial-type NOS) and calci-
um-independent (iNOS) isoenzymes.12 We hypothesized
that increased proinflammatory cytokines2 can activate
downstream inflammatory enzymes (eg, iNOS, MMP-2,
and MMP-9) and contribute to the myocardial dysfunction
that commonly follows CPB.13 We have previously shown
that increased NO delivery can reduce expression of neu-
trophil adhesion complex CD18.7 In contrast, our current
findings that an NO scavenger also decreases CD18 expres-
sion are novel and suggest that the source of NO is impor-
tant in the modulation of CD18 expression. Excessive NO
generation by iNOS is also associated with formation of
peroxynitrite, a potent oxidant. Peroxynitrite exerts a dual
effect on blood-cell adhesion because low concentrations of
peroxynitrite decrease and high concentrations increase leu-
kocyte and platelet activation.14 Thus adhesion-inhibitor
effects of pharmacologic NO could result from its antioxi-
dant properties,15 whereas scavenging of inducible NO by
AMD6221 could decrease excessive peroxynitrite genera-
tion and leukocyte activation.
Proinflammatory cytokines are increased after CPB2 and
can induce cardiac iNOS,16 which in turn impairs cardiac
function.17 Excessive cardiac NO decreases cardiac contrac-
tility18 through activation of cyclic guanosine monophos-
phate–dependent protein kinases or through increased per-
TABLE 1. Selected hemodynamic values
Baseline 1 h After 4 h After
PSA (mm Hg) Control-placebo 123 15 112 15 109 12
Control-6221 106 16 114 14 113 17
CPB-placebo 125 11 98 14* 101 18*
CPB-6221 142 9 89 13* 95 4*
PRA (mm Hg) Control-placebo 6 2 7 2 8 2
Control-6221 5 1 7 2 6 2
CPB-placebo 5 1 6 1 6 1
CPB-6221 6 1 8 2 7 2
PCWP (mm Hg) Control-placebo 8 2 8 1 9 1
Control-6221 6 1 7 1 6 1
CPB-placebo 8 2 9 2 8 2
CPB-6221 9 2 9 1 9 3
SVR (dyne  s1  cm5) Control-placebo 6503 1517 5461 1191 6347 1025
Control-6221 8403 1360 9452 2264 11143 2130*†
CPB-placebo 8112 2251 6898 1323 11672 918*
CPB-6221 9593 2713 7227 2062 11406 2812*
CO (L/min) Control-placebo 1.5 0.4 1.6 0.6 1.4 0.2
Control-6221 1.0 0.3 1.0 0.2 0.8 0.2
CPB-placebo 1.3 0.4 1.1 0.3 0.7 0.2*
CPB-6221 1.2 0.5 1.0 0.2 0.7 0.1*
Fluid requirements (mL) Control-placebo — — 2655 82‡
Control-6221 — — 892 159
CPB-placebo — — 1617 254‡
CPB-6221 — — 983 134
PCWP, Pulmonary capillary wedge pressure; SVR, systemic vascular resistance (calculated as SVR  PSA–PRA/CO 80).
*Significant difference (P  .05) compared with the other periods within the same group.
†Significant difference (P  .05) compared with the same period in the placebo group (control-placebo or CPB-placebo).
‡Significant difference (P  .05) comparing pooled groups (control-placebo vs control-6221 or CPB-placebo vs CPB-6221).
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Figure 2. Mean SD values of Ca2-dependent and Ca2-independent NOS activity. Values are shown for the lung
and brain. Note that in the brain Ca2-dependent NOS includes neuronal-type NOS. *Significant difference (P <
.05) between CPB (filled bars) and control (open bars) groups. #Significant difference between control and
AMD6221-treated groups (P < .05).
TABLE 2. Selected biochemical and hematologic values in all 4 groups
Baseline 1 h After 4 h After
Hemoglobin
(g/dL)
Control-placebo 10.9 1.3 9.9 1.5 9.0 1.2
Control-6221 11.7 0.7 11.4 0.8 11.9 0.8*†
CPB-placebo 12.5 0.8 6.7 0.4* 7.9 0.6*
CPB-6221 10.4 3.4 7.3 0.7* 7.6 1.1*
WCB
(109 cells)
Control-placebo 8.1 2.0 7.2 1.2 7.7 0.8
Control-6221 6.6 2.3 7.7 2.6 8.6 2.2
CPB-placebo 5.3 1.5 5.3 1.7 6.9 2.7
CPB-6221 6.0 1.4 5.4 1.7 6.7 1.7
PO2
(mm Hg)
Control-placebo 569 20 557 58 589 23
Control-6221 558 28 564 42 566 24
CPB-placebo 438 63 273 168* 276 135*
CPB-6221 442 52 303 144* 305 121*
PCO2
(mm Hg)
Control-placebo 39 5 41 3 40 2
Control-6221 32 10 34 7 34 8
CPB-placebo 36 7 36 4 39 5
CPB-6221 25 8 34 8 30 6
CD18
(units)
Control-placebo 65 11 71 8 66 7
Control-6221 53 25 51 31 35 26*†
CPB-placebo 69 22 78 15 81 11
CPB-6221 52 25 54 33 38 27†
WBC, White blood cell count corrected for hemodilution effect; CD18 expression, peak fluorescent intensity of neutrophils for CD18 (see text).
*Significant difference (P  .05) compared with other periods within the same group.
†Significant difference (P  .05) compared with the same period in the placebo group (control-placebo or CPB-placebo).
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oxynitrite formation.5 There is a balance between excessive
and insufficient NO needed to achieve optimum cardiac
function.19,20 We therefore hypothesized that an NO scav-
enger restricted to the intravascular space could prevent
injurious excessive NO but still allow regional vasoregula-
tion. In addition, scavenging by AMD6221 is favored in
high concentrations of NO because the reaction between the
scavenger and NO is second order,22 thereby reducing ex-
cessive NO with less effect on basal NO concentrations. Our
findings of improved hemodynamics in the AMD6221-
treated CPB group are consistent with this hypothesis. That
AMD6221 does not affect iNOS activity in the heart and
lung is also in keeping with previous cell-culture findings.10
We cannot explain the decrease in brain iNOS activity but
speculate that it might be as a result of altered feedback
control of brain iNOS.
MMPs and Heart Function
In the current study we have shown that MMP-2 and
MMP-9 activity in the heart is increased after CPB. In-
creased MMP activity, in turn, is associated with decre-
ments in cardiac function that might, in part, be due to
degradation of sarcomeres with resultant disorganization of
the contractile apparatus.23 There is extensive literature
documenting that altering the balance between MMPs and
tissue inhibitor of metalloproteinases toward increased
MMP activity plays a pathophysiologic role in the progres-
sion of cardiac dysfunction in congestive heart failure.4 We
have previously shown that increased NOS, MMP-2, and
MMP-9 activities are found within myocytes after CPB.3 In
the same study we also found that tissue inhibitor of met-
alloproteinases 4 expression is decreased, thus concluding
that CPB results in relatively unopposed increases in myo-
cardial MMP activities. We therefore now speculate that
increased iNOS activity increases plasma NO, which in turn
upregulates cardiac MMP activity. We further speculate that
administration of the NO scavenger AMD6221 by reducing
plasma NO prevents this cardiac upregulation of MMP
activities and thereby reduces postoperative cardiac dys-
function.
Noncardiac Organ Injury
Our findings of increased cardiac iNOS activity support
prior observations of CPB-associated increases of NO gen-
eration,25 and we have now extended these observations to
other organs, including brain and lungs. We have now
shown that CPB is associated with increased iNOS activity
in brain tissue. Although we do not have direct evidence that
Figure 3. Mean  SD values of MMP activity. Values are shown for the left atrium and left ventricle. *Significant
difference (P < .05) between CPB (filled bars) and control (open bars) groups.
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iNOS in this setting causes brain injury, there is evidence in
another model that increased NO production worsens cere-
bral function.26 We have found that AMD6221 ameliorates
the increased brain iNOS activity, suggesting that this might
serve as a therapeutic target to improve neural function after
CPB.
Carney and colleagues27 previously found that pharma-
cologic inhibition of MMPs ameliorated a porcine lung
injury after CPB. Our findings of increased MMP-2 and
MMP-9 activity after CPB confirm the biologic basis for the
relevance of their findings. We have extended these obser-
vations to also show that MMP-2 activity is increased in
brain samples after CPB. These observations link human
brain injury (eg, cerebral edema28 and neuronal dysfunc-
tion29) after CPB with the cellular changes (increased NOS
and MMP-2 activities) capable of causing these gross
changes.
NOS and MMP as Therapeutic Targets
The pharmacologic inhibition of these inflammatory en-
zymes could be clinically beneficial in preventing organ
dysfunction after CPB. We have previously shown that
infusion of GSNO, an NO donor, could ameliorate some of
the adverse sequellae of CPB.7 We now show that scaveng-
ing circulating NO can also improve hemodynamics and
decrease selected inflammatory enzymes activities. The he-
modynamic parameters we chose (mean blood pressure of
60 mm Hg with a PRA of at least 15 mm Hg) are similar
to the clinical parameters routinely followed after human
coronary artery bypass grafting surgery. The AMD6221-
treated animals were able to reach these end points with
decreased requirements for intravenous fluids, despite de-
creased requirements for phenylephrine compared with
those in the placebo-treated animals. This suggests that the
NO scavenging improved vascular tone, reduced intravas-
cular fluid transudation, or both. In addition, neutrophil
CD18 surface expression was decreased in the NO scaven-
ger–treated animals. Decreased neutrophil adhesion can
also reduce CPB-associated organ dysfunction.8
We have also shown that systemic infusion of that NO
scavenger can decrease MMP-2 activity in the brain after
CPB. This might be mediated through decreased peroxyni-
trite production because peroxynitrite is known to induce
MMP activity.21
In summary, there is a complex relationship among these
inflammatory mediators. The treatment with AMD6221 was
able to influence several aspects of the systemic inflamma-
Figure 4. Mean SD values of MMP activity. Values are shown for the lung and brain. *Significant difference (P <
.05) between CPB (filled bars) and control (open bars) groups.
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tory response after CPB. These potentially beneficial events
occurred without adversely affecting systemic vascular resis-
tance or CO. Therefore NO scavengers might represent a new
class of compounds to reduce the adverse effects of CPB.
References
1. Downing SW, Edmunds LH Jr. Release of vasoactive substances
during cardiopulmonary bypass. Ann Thorac Surg. 1992;54:1236-43.
2. Kawamura T, Wakusawa R, Okada K, et al. Elevation of cytokines
during open heart surgery with cardiopulmonary bypass: participation
of inteleukin 8 and 6 in the reperfusion injury. Can J Anaesth.
1993;40:1016-21.
3. Mayers I, Hurst T, Puttagunta L, et al. Cardiac surgery increases the
activity of matrix metalloproteinases and nitric oxide synthase in
human hearts. J Throrac Cardiovasc Surg. 2001;122:746-53.
4. Stetler-Stevenson WG, Krutsch HC, Liotta LA. Tissue inhibitor of
metalloproteinase (TIMP-2): a new member of the metalloproteinase
inhibitor family. J Biol Chem. 1989;264:17374-8.
5. Schulz R, Dodge K, Lopaschuk GD, et al. Peroxynitrite impairs
cardiac contractile function by decreasing cardiac efficiency. Am J
Physiol. 1997;272:H1212-9.
6. Fricker SP, Slade E, Powell NA, et al. Ruthenium complexes as nitric
oxide scavengers: a potential therapeutic approach to nitric oxide-
mediated diseases. Br J Pharmacol. 1997;122:1441-9.
7. Mayers I, Salas E, Hurst T, et al. Increased nitric oxide synthase
activity following canine cardiopulmonary bypass is suppressed by
S-nitroso-glutathione. J Thorac Cardiovasc Surg. 1999;117:1009-16.
8. Mayers I, Hurst T, Johnson D, et al. Anti-CD18 antibodies improve
cardiac function following cardiopulmonary bypass in dogs. J Crit
Care. 1996;11:189-97.
9. Radomski MW, Vallance PJ, Whitely G, et al. Modulation of platelet
adhesion to human vascular endothelium by the constitutive and
cytokine-inducible nitric oxide synthases. Cardiovasc Res. 1993;27:
1380-2.
10. Sawicki G, Salas E, Murat J, et al. Release of gelatinase A during
platelet activation mediates aggregation. Nature. 1997;386:616-8.
11. Mosi R, Seguin B, Cameron B, et al. Mechanistic studies on AMD-
6221: a ruthenium-based nitric oxide scavenger. Biochem Biophys Res
Commun. 2002;292:519-29.
12. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl
J Med. 1993;329:2002-12.
13. Breisblatt WM, Stein KL, Wolf CJ, et al. Acute myocardial dysfunc-
tion and recovery: a common occurrence after coronary bypass sur-
gery. J Am Coll Cardiol. 1990;15:1261-9.
14. Moro MA, Darley-Usmar V, Goodwin DA, et al. Paradoxical fate and
biological action of peroxynitrite on human platelets. Proc Natl Acad
Sci U S A. 1994;91:6702-6.
15. Wink DA, Hanbauer I, Krishna MC, et al. Nitric oxide protects again
cellular damage and cytotoxicity from reactive oxygen species. Proc
Natl Acad Sci U S A. 1993;90:9813-7.
16. Schulz R, Nava E, Moncada S. Induction and potential biologic
relevance of a Ca2-independent nitric oxide synthase in the myocar-
dium. Br J Pharmacol. 1992;105:575-80.
17. Schulz R, Panas DL, Catena R, et al. The role of nitric oxide in cardiac
depression induced by interleukin-1 beta and tumour necrosis factor-
alpha. Br J Pharmacol. 1995;114:27-34.
18. Kinugawa KI, Kohmoto O, Yao A, et al. Cardiac inducible nitric oxide
synthase negatively modulates myocardial function in cultured rat
myocytes. Am J Physiol. 1997;272:H35-47.
19. Lefer DJ, Nakanishi K, Johnston WE et al. Antineutrophil and myo-
cardial protecting actions of a novel nitric oxide donor after myocar-
dial ischemia and reperfusion in dogs. Circulation. 1993;88:2337-50.
20. Matheis G, Sherman MP, Buckberg GD et al. Role of L-arginine-nitric
oxide pathway in myocardial reoxygenation injury. Am J Physiol.
1992;262:H616-20.
21. Okamoto T, Akaike T, Nagano T, et al. Activation of human neutro-
phil procollagenase by nitrogen dioxide and peroxynitrite: a novel
mechanism for procollagenase activation involving nitric oxide. Arch
Biochem Biophys. 1997;342:261-74.
22. Fricker SP. Nitrogen monoxide-related disease and nitrogen monoxide
scavengers as potential drugs. In: Sigel A, Sigel H, editors. Metal ions
in biological systems. Vol. 36. New York: Marcel Dekker Inc; 1999.
p. 665-721.
23. Rouet-Benzineb P, Buhler JM, Dreyfus P, et al. Altered balance
between matrix gelatinases (MMP-2 and MMP-9) and their tissue
inhibitors in human dilated cardiomyopathy: potential role of MMP-9
in myosin-heavy chain degradation. Eur J Heart Fail. 1999;1:337-52.
24. Spinale FG, Coker ML, Bond BR, et al. Myocardial matrix degrada-
tion and metalloproteinase activation in the failing heart: a potential
therapeutic target. Cardiovasc Res. 2000;46:225-38.
25. Morita K, Sherman MP, Buckberg GD, et al. Studies of hypoxemic/
reoxygenation injury: without aortic clamping. V. Role of the L-
arginine-nitric oxide pathway: the nitric oxide paradox. J Thorac
Cardiovasc Surg. 1995;110:1200-11.
26. Segawa D, Hatori N, Yoshizu H, et al. The effect of nitric oxide
synthase inhibitor on reperfusion injury of the brain under hypother-
mic circulatory arrest. Thorac Cardiovasc Surg. 1998;115:925-30.
27. Carney DE, Lutz CJ, Picone AL, et al. Matrix metalloproteinase
inhibitor prevents acute lung injury after cardiopulmonary bypass.
Circulation. 1999;100:400-6.
28. Harris DN, Bailey SM, Smith PLC, et al. Brain swelling in first hour
after coronary artery bypass surgery. Lancet. 1993;342:586-7.
29. Roach GW, Kanchuger M, Mangano CM, et al. Adverse cerebral
outcomes after coronary bypass surgery. N Engl J Med. 1996;335:
1857-63.
Cardiopulmonary Support and Physiology Mayers et al
668 The Journal of Thoracic and Cardiovascular Surgery ● March 2003
CSP
